Sandoz, a division of Novartis, is a global leader in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 1886, Sandoz has established itself as a pioneer in generic and biosimilar medicines, focusing on high-quality, affordable healthcare solutions. With a strong presence in Europe, North America, and emerging markets, the company is dedicated to improving patient access to essential medications. Sandoz's core offerings include a diverse range of generic pharmaceuticals, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. The company has achieved significant milestones, including the launch of several groundbreaking biosimilars, solidifying its position as a trusted partner in the healthcare sector. With a commitment to sustainability and patient-centric solutions, Sandoz continues to shape the future of medicine.
How does Sandoz's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sandoz's score of 74 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Sandoz reported total carbon emissions of approximately 1,988,500,000 kg CO2e. This includes Scope 1 emissions of about 82,100,000 kg CO2e, Scope 2 emissions of approximately 157,600,000 kg CO2e, and significant Scope 3 emissions totalling around 1,748,800,000 kg CO2e. The previous year, 2023, saw total emissions of about 2,260,100,000 kg CO2e, with Scope 1 at approximately 86,200,000 kg CO2e, Scope 2 at around 122,300,000 kg CO2e, and Scope 3 emissions reaching about 2,051,700,000 kg CO2e. Sandoz has set ambitious climate commitments, aiming to reduce its Scope 1 emissions by 30% from a 2020 baseline by 2030. Additionally, the company targets near-zero Scope 1 and Scope 2 emissions by 2025. Furthermore, Sandoz is committed to achieving net-zero emissions across all scopes by 2050. These targets reflect the company's proactive approach to addressing climate change within the pharmaceutical sector, headquartered in Switzerland (CH). The emissions data and reduction initiatives are sourced directly from Sandoz Group AG, with no cascaded data from a parent organization.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Sandoz's Scope 3 emissions, which decreased by 15% last year and decreased by approximately 15% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sandoz has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Sandoz's sustainability data and climate commitments